Cargando…

Correction: Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169609/ http://dx.doi.org/10.1371/journal.pone.0108102

Ejemplares similares

Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2
por: Perfetti, Alessandra, et al.
Publicado: (2014)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
por: López-Martínez, Andrea, et al.
Publicado: (2020)

Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice
por: Oana, Kosuke, et al.
Publicado: (2013)

Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy
por: Hu, Ningyan, et al.
Publicado: (2023)

Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca(2+) signal in myotonic dystrophy type 1 myotubes
por: Santoro, Massimo, et al.
Publicado: (2020)

Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy
por: Wojtkowiak-Szlachcic, Agnieszka, et al.
Publicado: (2015)

Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1
por: Hu, Ningyan, et al.
Publicado: (2018)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
por: Wagner, Stacey D., et al.
Publicado: (2016)

Cell-type-specific dysregulation of RNA alternative splicing in short tandem repeat mouse knockin models of myotonic dystrophy
por: Nutter, Curtis A., et al.
Publicado: (2019)

HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1
por: O’Leary, Debra A., et al.
Publicado: (2010)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1
por: Klinck, Roscoe, et al.
Publicado: (2014)

Author Correction: Detection of aberrant splicing events in RNA-seq data using FRASER
por: Mertes, Christian, et al.
Publicado: (2022)

Myotonic dystrophy type 2: the 2020 update
por: Meola, Giovanni
Publicado: (2020)

Genome-Wide Identification of Evolutionarily Conserved Alternative Splicing Events in Flowering Plants
por: Chamala, Srikar, et al.
Publicado: (2015)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Correction to: What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review
por: Roussel, Marie-Pier, et al.
Publicado: (2019)

Differences in splicing defects between the grey and white matter in myotonic dystrophy type 1 patients
por: Nishi, Masamitsu, et al.
Publicado: (2020)

Autistic traits in myotonic dystrophy type 1 due to MBNL inhibition and RNA mis-splicing
por: Sznajder, Lukasz, et al.
Publicado: (2023)

Author Correction: Myotonic dystrophy RNA toxicity alters morphology, adhesion and migration of mouse and human astrocytes
por: Dincã, Diana M., et al.
Publicado: (2022)

Prolonged Corrected QT Interval in Patients with Myotonic Dystrophy Type 1
por: Park, Kang Min, et al.
Publicado: (2013)

Cardiac Conduction Disorders as Markers of Cardiac Events in Myotonic Dystrophy Type 1
por: Itoh, Hideki, et al.
Publicado: (2020)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Disease burden of myotonic dystrophy type 1
por: Landfeldt, Erik, et al.
Publicado: (2019)

Cardiac Pathology in Myotonic Dystrophy Type 1
por: Mahadevan, Mani S., et al.
Publicado: (2021)

Targeting Myotonic Dystrophy Type 1 with Metformin
por: García-Puga, Mikel, et al.
Publicado: (2022)

Targeted splice sequencing reveals RNA toxicity and therapeutic response in myotonic dystrophy
por: Tanner, Matthew K, et al.
Publicado: (2021)

Overexpression of CUGBP1 in Skeletal Muscle from Adult Classic Myotonic Dystrophy Type 1 but Not from Myotonic Dystrophy Type 2
por: Cardani, Rosanna, et al.
Publicado: (2013)

Deregulated MicroRNAs in Myotonic Dystrophy Type 2
por: Greco, Simona, et al.
Publicado: (2012)

Metabolic impairments in patients with myotonic dystrophy type 2
por: VUJNIC, MILORAD, et al.
Publicado: (2018)

Personality traits in patients with myotonic dystrophy type 2
por: Paunic, Teodora, et al.
Publicado: (2017)

Endometriosis as Initial Manifestation of Myotonic Dystrophy Type-2
por: Finsterer, Josef, et al.
Publicado: (2021)

Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
por: Peric, Stojan, et al.
Publicado: (2022)

Targeting nuclear RNA for in vivo correction of myotonic dystrophy
por: Wheeler, Thurman M., et al.
Publicado: (2012)

Induction and Reversal of Myotonic Dystrophy Type 1 Pre-mRNA Splicing Defects by Small Molecules
por: Childs-Disney, Jessica L., et al.
Publicado: (2013)

Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I
por: Bondy-Chorney, Emma, et al.
Publicado: (2016)

A comprehensive atlas of fetal splicing patterns in the brain of adult myotonic dystrophy type 1 patients
por: Degener, Max J F, et al.
Publicado: (2022)

Genomic organization and alternative splicing of the human and mouse RPTPρ genes: Correction
por: Besco, Julie A, et al.
Publicado: (2001)

Unexpected diagnosis of myotonic dystrophy type 2 repeat expansion by genome sequencing
por: Rafehi, Haloom, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_km8jeol3v5skc16m4qmcg62k7h